1. Home
  2. CDXS vs EVG Comparison

CDXS vs EVG Comparison

Compare CDXS & EVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDXS
  • EVG
  • Stock Information
  • Founded
  • CDXS 2002
  • EVG 2005
  • Country
  • CDXS United States
  • EVG United States
  • Employees
  • CDXS N/A
  • EVG N/A
  • Industry
  • CDXS Major Chemicals
  • EVG Investment Managers
  • Sector
  • CDXS Industrials
  • EVG Finance
  • Exchange
  • CDXS Nasdaq
  • EVG Nasdaq
  • Market Cap
  • CDXS 176.4M
  • EVG 144.8M
  • IPO Year
  • CDXS 2010
  • EVG N/A
  • Fundamental
  • Price
  • CDXS $2.46
  • EVG $10.95
  • Analyst Decision
  • CDXS Buy
  • EVG
  • Analyst Count
  • CDXS 2
  • EVG 0
  • Target Price
  • CDXS $11.00
  • EVG N/A
  • AVG Volume (30 Days)
  • CDXS 500.7K
  • EVG 49.4K
  • Earning Date
  • CDXS 05-14-2025
  • EVG 01-01-0001
  • Dividend Yield
  • CDXS N/A
  • EVG 8.68%
  • EPS Growth
  • CDXS N/A
  • EVG N/A
  • EPS
  • CDXS N/A
  • EVG N/A
  • Revenue
  • CDXS $59,345,000.00
  • EVG N/A
  • Revenue This Year
  • CDXS $12.62
  • EVG N/A
  • Revenue Next Year
  • CDXS $22.11
  • EVG N/A
  • P/E Ratio
  • CDXS N/A
  • EVG N/A
  • Revenue Growth
  • CDXS N/A
  • EVG N/A
  • 52 Week Low
  • CDXS $1.90
  • EVG $9.13
  • 52 Week High
  • CDXS $6.08
  • EVG $10.86
  • Technical
  • Relative Strength Index (RSI)
  • CDXS 51.79
  • EVG 55.12
  • Support Level
  • CDXS $2.23
  • EVG $10.80
  • Resistance Level
  • CDXS $2.59
  • EVG $10.99
  • Average True Range (ATR)
  • CDXS 0.14
  • EVG 0.19
  • MACD
  • CDXS 0.05
  • EVG 0.03
  • Stochastic Oscillator
  • CDXS 70.45
  • EVG 82.14

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.

Share on Social Networks: